Research
Current Research
Synopsis of studies currently recruiting
EX9536-4388 Semaglutide obesity study - sponsored by Novo Nordisk.
People who are overweight or who have obesity are at high risk for cardiovascular disease. Semaglutide has shown cardiovascular risk reduction and impact on cardiovascular risk factors including weight, high blood glucose and increased blood pressure in subjects with type 2 diabetes. Whether semaglutide will reduce cardiovascular disease risk and mortality in patients with established cardiovascular disease and who are overweight/obese is not known. The study’s primary objective is to demonstrate whether semaglutide injections lower the incidence of major adverse cardiovascular events versus semaglutide placebo, both added to standard care in patients with established cardiovascular disease and overweight/obesity. The study duration is 3 years, with 1-3 monthly health checks by the specialist and Registered Nurses. All participation, specialist consults and medication is free and travel expenses are reimbursed.
Amgen AMG 20170625 Versalius- sponsored by Amgen
One of the study objectives is to evaluate the effect of treatment with Evolocumab (Repatha), compared with placebo, in patients with high cardiovascular risk. Eligible patients will be without a prior heart attack or stroke but have elevated cholesterol levels whilst receiving optimized cholesterol lowering therapy.The study duration is 3 years, with 4 monthly health checks by the specialist and Registered Nurses. All participation, specialist consults and medication is free and travel expenses are reimbursed.
Amgen AMG890 20180109 Lp(a) - sponsored by Amgen
AMG 890 (delivered via a small injection into the top layer of skin by a Registered Nurse) is being developed for the treatment of patients with cardiovascular disease and elevated Lipoprotein Lp(a) levels, with the aim of reducing the risk of cardiovascular events. Lp(a) reductions of greater than 80% from baseline are anticipated with AMG 890 and it is expected that this level of reduction in Lp(a) may result in meaningful health benefits in patients with cardiovascular disease. The study duration is 1.5 years, with 3 monthly health checks by the Specialist and Registered Nurses. All participation, specialist consults and medication is free and travel expenses are reimbursed.
List of studies conducted in the last 15 years
2005 – 2006 | Gemini AALA A3841024
An International multi-centre trial sponsored by Pfizer International Pty Ltd.
2005 – 2006 | AI-700-32 contrast trial
An International multi- centre trial sponsored by Acusphere Inc.
2005 – 2007 | A5091043 Illuminate
An International multi-centre trial sponsored by Pfizer International Pty Ltd.
2005 – 2006 | Familial Hypercholesterolemia A5091026
An International multi-centre trial sponsored by Pfizer International Pty Ltd.
2006 – 2007 | MK0524A/020
An International multi-centre trial sponsored by Merck Pty Ltd.
2007 – disbanded | A5091075
An International multi-centre trial sponsored by Pfizer International Pty. Ltd.
2007 – 2008 | PACE Study, AI-700
Contrast follow-up study sponsored by Acusphere Inc.
2007 – 2008 | MK0524A/067
An International multi-centre trial sponsored by Merck Pty Ltd.
2007 – 2009 | MK6213/006
An international multi-centre trial sponsored by Merck Pty Ltd.
2007 – disbanded | MK0524a/041
An international multi-centre trial sponsored by Merck Pty Ltd.
2007 – disbanded | MK0524B/024
An international multi-centre trial sponsored by Merck Pty Ltd.
2008 – 2010 | MK0859/019
An international multi-centre trial sponsored by Merck Pty Ltd.
2008 – disbanded | MK0524A/082
An international multi-centre trial sponsored by Merck Pty Ltd.
2008 – 2009 | WHICH Heart failure study
A multi site study sponsored by the Baker Heart Research Institute Melbourne.
2008 – 2009 | EFC6910
An international multi-centre trial sponsored by Sanofi Aventis Pty Ltd.
2009 – 2009 | EFC10841
An international multi-centre trial sponsored by Sanofi Aventis Pty Ltd
2009 – 2009 | MK0524A/102
An international multi-centre trial sponsored by Merck Pty.Ltd
2009 – 2011 | MB117-004
An international multi-centre trial sponsored by Bristol Myers- Squibb Pty Ltd
2010 – 2014 | MK0859/019/011
An international multi-centre trial sponsored by Merck Pty Ltd.
2010 – 2011 | Enoxaparin therapy in post cardiac MI patients
Co Investigator for an Investigator initiated trial (Dr Michael Barras – Head of Pharmacy Mater Adult Hospital)
2010 – 2017 | CSPP100F2301- Atmosphere
An International multi centre trial sponsored by Novartis Pty Ltd
2010 – 2017 | 28431754DIA3008 Canvas
An International multi centre trial sponsored by Johnson & Johnson Pty Ltd
2010 – 2012 | DRONE- C-03668 Artemis
An International multi centre trial sponsored by Sanofi Aventis
2011 – 2013 | MK0524A/133
An international multi-centre trial sponsored by Merck Pty Ltd
2011 – 2012 | MK0524A/118
An international multi-centre trial sponsored by Merck Pty Ltd
2011 – 2013 | Nicotinic Acid effects on Lipoprotein(a)
Co Investigator for an investigator initiated Trial (Dr Karam Kostner).
2012 – 2015 | MIPO3801011- Mipomersen
An International multi centre trial sponsored by Genzyme Pty Ltd.
2012 – 2014 | AMR-01-01-0019, Reduce-it
An international multicentre trial sponsored by Amarin Pharma Inc.
2012 – 2017 | AMG 145 20110118, Fourier study
An international multicentre trial sponsored by Amgen Pty Ltd.
2012 – 2014 | BC28027 Aleglitazar
An international multicentre trial sponsored by Roche Pty Ltd
2013 – 2014 | Regeneron CL 1110
An international multicentre trial sponsored by Regeneron Pharmaceuticals Inc
2013 – 2014 | Regeneron CL 1118
An international multicentre trial sponsored by Regeneron Pharmaceuticals Inc
2013 – Dec 2017 | EFC13786 Odyssey choice II
An international multicentre trial sponsored by Sanofi Pharmaceuticals inc
2013 – Jan 2018 | Amgen 20120332 GAUSS 3
An international multicentre trial sponsored by Amgen Pty Ltd
2014 – June 2018 | Amgen 20120138 OSLER 2
An international multicentre trial sponsored by Amgen Pty Ltd
2015 – present | Strength D5881C00004
An international multicentre trial sponsored by Astra Zeneca
2017 – May 2018 | Chong Kun Dang Pharmaceutical Corporation 148HL16011, CKD-519
An international multicentre trial sponsored by CKD
2017 – Dec 2017 | Amgen 20110203 OM Amg 423
An international multicentre trial sponsored by Amgen Pty Ltd
2017 – November 2018 | SAHMRI Impact study
A multicentre trial sponsored by Heart Health/Investigator
2017 – present | Esperion Therapeutics 1002-043, Bempedoic Acid
An international multicentre trial sponsored by Esperion Therapeutics
2018 – 2020 | BI Heart Failure trial 1245-121
An international multicentre trial sponsored by Boehringer Ingelheim
2018 – present | EX9536-4388 Semaglutide obesity study
An international multicentre trial sponsored by Novo Nordisk
2019 – present | CTQJ230A12001 Lp(a) non interventional study
Novartis
2019 – present | Amgen AMG 20170625 Versalius
An international multicentre trial sponsored by Amgen
2020 – present | Amgen AMG890 20180109 Lp(a)
An international multicentre trial sponsored by Amgen